P2Y(12) antagonists as antiplatelet agents - Recent developments.

Abstract

Antiplatelet therapy is a crucial component of disease management for patients with acute coronary syndromes or chronic stable coronary disease, as well as individuals undergoing percutaneous coronary intervention with stent implantation. Antiplatelet therapy includes the administration of aspirin and clopidogrel, either alone or in combination, which act through the inhibition of thromboxane A2 generation and blockade of the Gi-coupled P2Y12 purinergic receptor, respectively. Because of the selective expression and specific functions of P2Y12 , this receptor has become an important antiplatelet drug target. P2Y12 antagonists can be broadly classified as either irreversible or reversible. Clopidogrel, an irreversible P2Y12 antagonist, has a delayed onset of action and high inter-individual variability. Limitations of clopidogrel have necessitated the discovery of novel P2Y12 antagonists with superior pharmacological profiles. This review summarizes recent studies on novel P2Y12 antagonists and the clinical implications and limitations of these agents.

• Authors: Kamala Bhavaraju, Azad Mayanglambam, A Koneti Rao, Satya P Kunapuli
• Journal: Current opinion in drug discovery & development (Curr Opin Drug Discov Devel) Vol. 13 Issue 4 Pg. 497-506 (Jul 2010) ISSN: 2040-3437 [Electronic] England
• PMID: 20597033 (Publication Type: Journal Article, Review)

Chemical References

• P2RY12 protein, human
• Platelet Aggregation Inhibitors
• Purinergic P2 Receptor Antagonists
• Receptors, Purinergic P2Y12

Topics

• Animals
• Clinical Trials as Topic
• Coronary Disease (drug therapy)
• Drug Discovery (methods, trends)
• Humans
• Models, Molecular
• Platelet Aggregation Inhibitors (chemistry, pharmacology, therapeutic use)
• Purinergic P2 Receptor Antagonists
• Receptors, Purinergic P2Y12